secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001628280-24-007579
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell reports Q4 net loss $52.9M, full-year loss $234.6M; cash $562.7M supports pipeline into 2027
--------------------------------------------------------------------------------

- Net loss $52.9M in Q4 2023 and $234.6M full year; non-GAAP net loss $43.9M Q4 and $177.4M FY.
- Revenue $0.1M in FY2023 vs $84.7M in FY2022 due to termination of GSK collaboration in Dec 2022.
- Cash $562.7M as of Dec 31, 2023; expected to fund operations into 2027.
- Expect initial clinical data from LYL797 CAR T in H1 2024 and LYL845 TIL in H2 2024; LYL845 got FDA Orphan Drug Designation for melanoma.
- Appointed Matt Lang as Chief Business Officer; IND submission for LYL119 expected H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828024007579/0001628280-24-007579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828024007579/lyel-20240228.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-007579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer